Evidence map›Paper›PMID 30361418›Full record

Trial reportHaematologica2019

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A Wang, Sherry Pierce, Sergej N Konoplev, Haitham Khogeer, Jeffrey L Jorgensen, Marina Konopleva and 5 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. [Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Evgeniya AngelovaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Charlene AudetteImmunoGen, Inc., Waltham, MA.
Yelena KovtunImmunoGen, Inc., Waltham, MA.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sa A WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sherry PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sergej N KonoplevDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Haitham KhogeerDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jeffrey L JorgensenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick A Zweidler-McKayImmunoGen, Inc., Waltham, MA.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elias J JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX jkhoury@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USImmunoGen (United States) · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the

Indexed as

Drug Delivery SystemsInterleukin-3 Receptor alpha SubunitNeoplasm ProteinsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCell Line, TumorChildChild, PreschoolFemaleGene Expression Regulation, LeukemicHumansAntineoplastic Agents, ImmunologicalIL3RA protein, humanImmunoconjugatesInterleukin-3 Receptor alpha SubunitNeoplasm Proteins

Identifiers

PMID30361418
PMCPMC6442980
OpenAlexW2898159047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.